thalidomide has been researched along with an2728 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feldman, SR; Moustafa, F | 1 |
| Lacour, JP | 1 |
| Bissonnette, R; Boguniewicz, M; Guttman-Yassky, E; Hanifin, JM; Kilty, I; Purohit, V; Tallman, AM; Wollenberg, A; Zielinski, MA | 1 |
| Kataoka, S; Nakajima, K; Sano, S; Takaishi, M | 1 |
2 review(s) available for thalidomide and an2728
| Article | Year |
|---|---|
A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic AMP; Dermatitis, Atopic; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Psoriasis; Thalidomide; Tissue Distribution | 2014 |
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Topics: Acetamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermatitis, Atopic; Drug Approval; Humans; Immune System; Inflammation; Phosphodiesterase Inhibitors; Phthalic Acids; Pyridines; Quinazolines; Risk; Skin; Thalidomide | 2019 |
2 other study(ies) available for thalidomide and an2728
| Article | Year |
|---|---|
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
Topics: Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP; Cyclopropanes; Down-Regulation; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1alpha; Interleukin-8; Keratinocytes; MAP Kinase Signaling System; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2020 |